Monitoring the Prevalence of Antimicrobial Resistance in Companion Animals: Results from Clinical Isolates in an Italian University Veterinary Hospital
Table 7
Nonsusceptibility percentages for every single tested drug considering the 138 isolates from specific specimens (blood cultures, urines from suspected HA UTIs, SSIs, and surgical implants), collected from cats and dogs referred to a University Veterinary Hospital between September 2020 and November 2022.
Blood cultures (n = 49)
Urines from suspected HA UTIs (N = 42)
SSIs and surgical implants (n = 49)
Amikacin
11.36% (5/44)
12.12% (4/33)
12.50% (5/40)
Gentamicin
26.67% (12/45)
41.02% (16/39)
45.45% (20/44)
Ampicillin
58.82% (20/34)
75.86% (22/29)
70.27% (26/37)
Amoxicillin–clavulanate
35.13% (13/37)
45.95% (17/37)
45.95% (17/37)
Piperacillin–tazobactam
24.49% (12/49)
33.33% (14/42)
34.69% (17/49)
Cefazolin/cephalotin
51.35% (19/37)
61.29% (19/31)
57.58% (19/33)
Ceftiofur
46.67% (21/45)
51.51% (17/33)
59.52% (25/42)
Tetracycline
67.39% (31/46)
69.05% (29/42)
67.35% (33/49)
Erythromycin
73.33% (11/15)
81.82% (9/11)
68.42% (13/19)
Clindamycin
73.33% (11/15)
81.82% (9/11)
68.42% (13/19)
Enrofloxacin
55.10% (27/49)
71.43% (30/42)
73.47% (36/49)
Trimethoprim–sulfamethoxazole
36.95% (17/46)
51.28% (20/39)
56.52% (26/46)
% AMR
81.63% (40/49)
90.48% (38/42)
93.88% (46/49)
% MDR
61.22% (30/49)
69.05% (29/42)
73.47% (36/49)
Note: the total number of nonsusceptible isolates out of the total number of tested isolates is reported in bracket.
